Related Experiment Video
Updated: Apr 21, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
8.2K
Fixed-dose combination therapy in type 2 diabetes mellitus
Lawrence Blonde1, Zinnia T San Juan2, Peggy Bolton1
1Department of Endocrinology, Diabetes and Metabolic Diseases, Ochsner Medical Center, New Orleans, Louisiana.
Summary
Fixed-dose combinations (FDCs) for type 2 diabetes mellitus simplify treatment by reducing pill burden and improving tolerability. Metformin extended-release (XR) FDCs offer efficacy with once-daily dosing and fewer gastrointestinal events, potentially enhancing patient adherence.
Area of Science:
- Endocrinology
- Pharmacology
- Internal Medicine
Background:
- Type 2 diabetes mellitus (T2DM) management often involves multiple antihyperglycemic agents.
- Challenges in combination therapy include pill burden, frequent dosing, and poor tolerability, leading to suboptimal adherence and outcomes.
- Fixed-dose combinations (FDCs) offer a strategy to simplify treatment regimens and improve patient adherence.
Purpose of the Study:
- To evaluate the efficacy and tolerability of fixed-dose combinations (FDCs) in managing type 2 diabetes mellitus.
- To provide an overview of dosing, costs, and adherence associated with FDCs.
- To specifically examine FDCs containing metformin extended-release (XR) for once-daily administration.
Main Methods:
- A literature review was conducted focusing on FDCs for T2DM management.
- Particular attention was given to FDCs incorporating metformin extended-release (XR) formulations.
- The review analyzed studies assessing efficacy, tolerability, dosing, cost-effectiveness, and adherence.
Main Results:
- Many FDCs include metformin; however, immediate-release (IR) metformin requires twice-daily dosing and can cause gastrointestinal (GI) side effects.
- Metformin XR formulations allow once-daily dosing and demonstrate reduced GI adverse effects compared to metformin IR.
- FDCs containing metformin XR offer potential advantages in simplifying regimens and improving tolerability.
Conclusions:
- FDCs containing metformin XR provide comparable efficacy to separate metformin IR formulations but with reduced dosing frequency and fewer GI events.
- These FDCs significantly decrease pill burden compared to multiple separate pills.
- By enhancing tolerability and simplifying regimens, FDCs have the potential to improve medication adherence in T2DM patients.
Related Concept Videos
01:01Dosage Regimen: Fixed Dose
2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:26Type II Diabetes I: Introduction
5
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
5
01:22Diabetes Mellitus: Type 2 and Gestational
4.8K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.8K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
982
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
982